NYGC
Bipolar Funding Consortium Aims to Unravel Disorder's Genetics, Reduce Healthcare Disparities
Premium
The ambitious set of projects funded by BD² aims to improve our understanding of bipolar disorder and inform care across the entire spectrum of research and clinical practice.
Immune Checkpoint Blockade Response Linked to Recurrent Mutations in Genes, Pathways
Exome sequences for hundreds of cancer patients led researchers to four recurrently mutated genes and several pathways with ties to immunotherapy response.
A New York Genome Consortium-led team plans retrospective and prospective analyses on very rare cancers in the hopes of improving treatment options available for patients.
Weill Cornell, NYGC Group to Commercialize WGS Circulating Tumor DNA Cancer Recurrence Assay
Premium
The assay monitors mutations across a patient's genome and matches them to mutations found in a patient's resected tumor and in DNA in the bloodstream.